Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is 77.55% higher on its value in year-to-date trading and has touched a low of $6.07 and a high of $15.84 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PHAT stock was last observed hovering at around $15.72 in the last trading session, with the day’s gains setting it 0.49%.
Currently trading at $16.21, the stock is 30.65% and 38.96% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing 3.12% at the moment leaves the stock 67.75% off its SMA200. PHAT registered 10.95% gain for a year compared to 6-month gain of 50.37%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 40.35% loss in the last 1 month and extending the period to 3 months gives it a 60.81%, and is 24.88% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.43% over the week and 6.93% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 452 employees, a market worth around $1.11B and $9.92M in sales. Profit margin for the company is -2995.66%. Distance from 52-week low is 167.27% and 2.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-113.44%).
Phathom Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -1.49 with sales reaching $12.61M over the same period.The EPS is expected to shrink by -42.48% this year, but quarterly earnings will post 6,382.40% year-over-year.
169.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 105.78% of the company’s shares. The shares outstanding are 57.97M, and float is at 32.38M with Short Float at 44.00%. Institutions hold 96.44% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.3189 of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.788 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9906 and valued at over $35.84 million, while INVESCO LTD. holds 5.3853 of the shares totaling 3.14 million with a market value of $32.38 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider sale by Nabulsi Azmi, the company’s Chief Operating Officer. SEC filings show that Nabulsi Azmi sold 10,901 shares of the company’s common stock on Jul 15 ’24 at a price of $11.72 per share for a total of $0.13 million. Following the sale, the insider now owns 0.24 million shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Jul 15 ’24 that Henderson Molly (CFO and CBO) sold a total of 4,325 shares of the company’s common stock. The trade occurred on Jul 15 ’24 and was made at $11.72 per share for $50689.0. Following the transaction, the insider now directly holds 99447.0 shares of the PHAT stock.
Still, SEC filings show that on Jul 15 ’24, Curran Terrie (President and Chief Executive) disposed off 33,848 shares at an average price of $11.72 for $0.4 million. The insider now directly holds 377,734 shares of Phathom Pharmaceuticals Inc (PHAT).
